三優(yōu)生物與Medicovestor簽訂戰(zhàn)略合作協(xié)議，協(xié)同開發(fā)新一代化療免疫ADC
中國上海·美國紐約 2025年6月10日，三優(yōu)生物醫(yī)藥（上海）有限公司（以下簡稱“三優(yōu)生物”）宣布與美國Medicovestor, Inc.（以下簡稱“Medicovestor”）簽訂戰(zhàn)略合作協(xié)議，共同推進(jìn)新一代First in class化療免疫抗體偶聯(lián)藥物（“化療免疫”型ADC）的開發(fā)。
▲ Medicovestor 與三優(yōu)生物簽訂戰(zhàn)略合作協(xié)議
Medicovester COO Lin Ong，白帆總經(jīng)理譚凱、商務(wù)負(fù)責(zé)人羅武松，三優(yōu)研發(fā)副總裁鄭海亮、外聯(lián)部經(jīng)理陳美玲共同見證
該合作協(xié)議已于2025年6月6日正式簽署。雙方將結(jié)合三優(yōu)生物全球領(lǐng)先的智能超萬億分子庫（AI-STAL）技術(shù)和智能化藥物篩選與臨床前研究，以及Medicovestor專有的ADC平臺技術(shù)——包括創(chuàng)新型二聚抗體結(jié)構(gòu)平臺ADoBindTM與雙表位靶向系統(tǒng)ADoTopeTM，致力于加速開發(fā)用于腫瘤和自身免疫性疾病治療的新一代化療免疫抗體偶聯(lián)藥物。
Medicovestor是一家美國生物技術(shù)公司，致力于開發(fā)新一代化療免疫ADC，用于治療癌癥和自身免疫性疾病。公司擁有兩大專有技術(shù)平臺，能以更低劑量實(shí)現(xiàn)更高療效，并支持聯(lián)合療法。其主導(dǎo)項(xiàng)目已進(jìn)入IND-enabling階段，其中針對胰腺癌的療法已提交FDA Orphan Drug Designation申請。公司目前持有11項(xiàng)授權(quán)專利和3項(xiàng)待批專利，在ADC領(lǐng)域具有獨(dú)特優(yōu)勢。
Medicovestor創(chuàng)始人Seah Lim博士深耕生物醫(yī)藥領(lǐng)域25年，是全球頂尖的轉(zhuǎn)化醫(yī)學(xué)科學(xué)家。在學(xué)術(shù)界，Seah博士曾擔(dān)任英國和美國多所大學(xué)（包括布朗大學(xué)和匹茲堡大學(xué)醫(yī)學(xué)院等）的全職教授，并多次擔(dān)任領(lǐng)導(dǎo)職務(wù)（科主任等）；在工業(yè)界，Seah博士曾擔(dān)任Bausch Health、Genzyme和Burroughs Wellcome & Company等公司的產(chǎn)品研發(fā)顧問，并曾任賽諾菲（Sanofi）公司全球項(xiàng)目的兒科負(fù)責(zé)人以及獨(dú)立董事和Genie Therapeutics, Inc.的商業(yè)與科學(xué)顧問。Seah博士不僅具備深厚的科學(xué)和行業(yè)背景，還擁有豐富的臨床實(shí)踐經(jīng)驗(yàn)。
▲ Medicovestor CEO Seah Lim博士和三優(yōu)生物CEO郎國竣博士
Medicovestor創(chuàng)始人兼CEO Seah Lim博士表示：“此次合作體現(xiàn)了我們對ADC重新定義的承諾——通過將我們差異化的平臺與三優(yōu)生物在抗體開發(fā)方面的世界級專業(yè)技術(shù)相融合，實(shí)現(xiàn)在ADC中整合免疫治療的創(chuàng)新理念。雙方的互補(bǔ)優(yōu)勢將共同推動突破性療法的開發(fā)，為治療選擇有限的患者帶來新希望！”
三優(yōu)生物創(chuàng)始人兼CEO郎國竣博士表示：“我們非常高興能與Medicovestor開展合作，推動其高度創(chuàng)新的化療免疫ADC走向臨床。通過緊密協(xié)同技術(shù)互補(bǔ)，我們希望共同打造改變患者生活的變革性療法惠及全球患者！”
本次戰(zhàn)略合作內(nèi)容包括聯(lián)合研究、技術(shù)轉(zhuǎn)移與領(lǐng)先候選藥物的共同開發(fā)。雙方計劃在未來幾個季度公布項(xiàng)目進(jìn)展與候選藥物篩選結(jié)果。
關(guān)于Medicovestor
Medicovestor是一家總部位于美國紐約的生物技術(shù)公司，專注于開發(fā)用于腫瘤和自身免疫性疾病治療的化療免疫抗體偶聯(lián)藥物（ADC）。公司的兩項(xiàng)專有平臺技術(shù)——ADoBind（創(chuàng)新型二聚抗體結(jié)構(gòu)）和ADoTope（雙效載藥靶向技術(shù)）旨在提升腫瘤選擇性并降低系統(tǒng)性毒性，從而釋放出超越傳統(tǒng)ADC應(yīng)用的新治療潛力。
關(guān)于三優(yōu)生物
三優(yōu)生物是一家以“運(yùn)用創(chuàng)新生物藥提高人類的生活品質(zhì)”為愿景，以“讓天下沒有難做的創(chuàng)新生物藥”為使命的生物醫(yī)藥高新技術(shù)企業(yè)。公司總部位于中國上海，在美國、歐洲等地設(shè)有子公司，現(xiàn)有投產(chǎn)及布局的研發(fā)及GMP場地20000多平方米。
公司以智能超萬億分子庫為核心，打造了國際領(lǐng)先的創(chuàng)新生物藥臨床前智能化及一體化研發(fā)平臺，通過“新藥發(fā)現(xiàn)、臨床前研究、智能化藥物研發(fā)及前沿科學(xué)研究”等四個維度加速創(chuàng)新生物藥物的研發(fā)進(jìn)程。
公司為合作伙伴提供“差異化CRO、整合型CDO、協(xié)同型CPO、特色CRS”于一體的“創(chuàng)新生物藥4C綜合業(yè)務(wù)”。公司已建立全球營銷網(wǎng)絡(luò)，已與全球1200多家藥企、生技公司等建立了良好的合作關(guān)系；已完成了1200多個新藥發(fā)現(xiàn)及開發(fā)服務(wù)項(xiàng)目；已完成了50多個合作研發(fā)項(xiàng)目，其中9個合作項(xiàng)目已完成臨床申報；公司開發(fā)了數(shù)千種品牌試劑。
公司已獲得國家高新技術(shù)、上海市專精特新、上海市小巨人和上?！皬埥恰逼髽I(yè)認(rèn)定。
Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
Shanghai, China & New York, USA — June 10, 2025 — Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs).
▲ Medicovestor and Sanyou Biopharmaceuticals signed a strategic partnership agreement, witnessed by Medicovestor COO Lin Ong; Dragon sail pharmaceutical General Manager Kai Tan and Business Director Wusong Luo; Sanyou Biopharmaceuticals Vice President of R&D Hailiang Zheng; and Outreach Manager Meiling Chen.
The agreement, officially signed on June 6, brings together Medicovestor’s proprietary ADC platforms—ADoBind, a novel dimeric antibody architecture, and ADoTope, a bi-epitope targeting system—with Sanyou’s globally leading AI-STAL (Artificial Intelligence-enabled Super Trillion Antibody Library) technology and intelligent drug screening and preclinical research capabilities. The collaboration aims to accelerate the development of first-in-class chemoimmunotherapies for oncology and autoimmune diseases so that it is “chemoimmunotherapy” ADCs.
Medicovestor is a U.S.-based biotechnology company dedicated to developing next-generation chemoimmunotherapies antibody-drug conjugates (ADCs) for the treatment of cancer and autoimmune diseases. The company has two proprietary technology platforms that enable higher efficacy at lower doses and support combination therapies. Its lead program has entered the IND-enabling stage, with a pancreatic cancer therapy submitted for FDA Orphan Drug Designation. Medicovestor currently holds 11 granted patents and 3 pending applications, positioning the company with a distinct competitive edge in the ADC field.
Dr. Seah Lim, Founder of Medicovestor, has over 25 years of experience in the biopharmaceutical industry and is recognized as a leading global expert in translational medicine. In academia, Dr. Lim has served as a full professor at several prestigious universities in the United Kingdom and the United States, including Brown University and the University of Pittsburgh School of Medicine, where he held multiple leadership positions such as Division Chief. In industry, he has worked as a Product Development Consultant for companies including Bausch Health, Genzyme, and Burroughs Wellcome & Company. He also served as the Pediatric Lead in the Global Program at Sanofi and has held advisory roles such as Independent Director and Commercial & Scientific Advisor at Genie Therapeutics, Inc. Dr. Seah Lim brings not only deep scientific and industry expertise but also extensive clinical experience to the company.
▲ Dr. Seah Lim, CEO of Medicovestor, and Dr. Guojun Lang, CEO of Sanyou Biopharmaceuticals “This partnership reflects our commitment to redefining ADCs by integrating our differentiated ADC platforms with Sanyou’s world-class expertise in antibody development to incorporate immunotherapy into ADCs,” said Seah Lim, MD, PhD, Founder and CEO of Medicovestor. “Together, our complementary strengths create a powerful engine to unlock novel therapeutic possibilities for patients with limited treatment options.”
“We are excited to collaborate with Medicovestor to realize the promise of their highly innovative chemoimmunotherapy ADC platforms,” said David Lang, PhD, Founder and CEO of Sanyou Biopharmaceuticals. “By combining scientific excellence with execution capability, we aim to deliver transformative therapies that change patients’ lives.”
The partnership includes joint research, technology transfer, and co-development of lead candidates. Both companies plan to announce development milestones and candidate selections in the coming quarters.
About Medicovestor, Inc.
Medicovestor is a biotechnology company headquartered in New York City, focused on advancing chemoimmunotherapy antibody-drug conjugates (ADCs) for oncology and autoimmune diseases. The company’s proprietary platforms—ADoBind, a novel dimeric antibody structure, and ADoTope, a dual-payload targeting technology—are designed to enhance tumor selectivity and minimize systemic toxicity, unlocking new therapeutic potential beyond conventional ADC applications.
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a high-tech biopharmaceutical company with the vision of "improving the quality of human life through innovative biologics" and the mission of " to make the R&D easy for innovative biologics". The company is headquartered in Shanghai, China, with subsidiaries in the United States, Europe, and other regions. It has over 20,000 square meters of R&D and GMP facilities that are currently in operation or under planning.
The company has established a world-leading preclinical intelligent and integrated R&D platform for innovative biologics, centered around an innovative platform of super-trillion antibody library. This platform accelerates the development of innovative biologics across four dimensions: new drug discovery, preclinical research, AI-assisted drug development, and frontier scientific research.
Sanyou provides a comprehensive "4C" business model for innovative biologics, combining differentiated CRO, integrated CDO, collaborative CPO, and specialized CRS. The company has built a global marketing network and established business with over 1,200 pharmaceutical and biotech companies worldwide. It has completed more than 1,200 new drug discovery and development service projects, with over 50 collaborative R&D projects, including 9 that have obtained IND approval. The company has also developed thousands of RUO reagents. Sanyou has also received a number of nationwide and Shanghai recognitions and awards.
